OncoCyte (OCX)

• Market cap: $84.7M
• 1 day: -3.27%
• 5 days: -2.31%
• 1 month: 6.47%
• 3 months: 27.04%
• 6 months: -1.00%
• Year to date: 27.04%
• 1 year: -0.67%
• 5 years: -92.95%
• 10 years: -98.17%
• Sector: Healthcare
• Industry: In Vitro & In Vivo Diagnostic Substances

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

500% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 1

100% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]

33% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 6

25% more funds holding

Funds holding: 20 [Q3] → 25 (+5) [Q4]

2% less capital invested

Capital invested by funds: $20.4M [Q3] → $20M (-$396K) [Q4]

3.63% less ownership

Funds ownership: 53.6% [Q3] → 49.97% (-3.63%) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $4 35% upside
• Avg. target: $4.42 49% upside
• High target: $5 69% upside

3 analyst ratings

• positive: 2 67%
• neutral: 1 33%
• negative: 0 0%

Lake Street Thomas Flaten 60% 1-year accuracy 6 / 10 met price target	69% upside $5	Buy Initiated	28 Mar 2025
Stephens & Co. Mason Carrico 18% 1-year accuracy 5 / 28 met price target	35% upside $4	Equal-Weight Reiterated	26 Mar 2025
Needham Mike Matson 40% 1-year accuracy 50 / 124 met price target	44% upside $4.25	Buy Reiterated	25 Mar 2025